ADC Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2023 07:15 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, June 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...
Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12
May 25, 2023 17:01 ET
|
Cybrexa Therapeutics
Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with CBX-12Dose-Limiting Toxicity Identified as...
Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology
May 25, 2023 04:00 ET
|
Oxford BioTherapeutics
Oxford, UK and San Jose, Calif., 25 May 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
May 04, 2023 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
April 24, 2023 18:15 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi
April 17, 2023 13:30 ET
|
Myricx Pharma
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload...
Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations
April 12, 2023 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., April 12, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
BioNTech und DualityBio schließen globale strategische Kollaboration – beschleunigte Entwicklung von differenzierten Antikörper-Wirkstoff-Konjugaten zur Therapie von soliden Tumoren im Fokus
April 03, 2023 06:45 ET
|
BioNTech SE
BioNTech erhält von DualityBio exklusive, globale Lizenzen für zwei sich in der Entwicklung befindenden Antikörper-Wirkstoff-Konjugate (DB-1303 und DB-1311); die Kandidaten richten sich gegen...
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
April 03, 2023 06:45 ET
|
BioNTech SE
BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human...
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023
March 14, 2023 17:58 ET
|
Mablink
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 In vivo antitumor efficacy with significant tumor growth inhibition in multiple...